RS
TBPH icon

R Squared’s Theravance Biopharma TBPH Stock Holding History

R Squared’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,737
Closed -$294K – 659
2025
Q4 		$294K Sell
15,737
-3,884
-20% -$64.4K 0.14% 235
2025
Q3 		$286K Sell
19,621
-355
-2% -$4.49K 0.12% 268
2025
Q2 		$220K Buy
19,976
+7,454
+60% +$72.5K 0.12% 281
2025
Q1 		$112K Buy
12,522
+10,822
+637% +$101K 0.12% 222
2024
Q4 		$16K Buy
+1,700
New +$15.5K 0.02% 983

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

R Squared's TBPH Position: Q1 2026 in Review

R Squared sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 15,737 shares — an estimated $294K sold.

R Squared first reported a position in TBPH in Q4 2024 and held it in 5 quarters. The position peaked at $294K in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • R Squared reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 15,737 Theravance Biopharma shares in Q1 2026, an estimated $294K.
  • R Squared first reported a position in Theravance Biopharma in Q4 2024 and held it in 5 quarters.
  • R Squared's Theravance Biopharma position peaked at $294K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.